Cooley represented Nuvation Bio in the transaction, and Sidley Austin represented Sagard Healthcare Partners. Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the...
Sagard Healthcare Partners’ $250 Million Non-Dilutive Financings to Nuvation Bio
Angion’s Merger Agreement with Elicio Therapeutics
Cooley advised Angion on the deal. Angion, a clinical-stage biopharmaceutical company, announced its definitive merger agreement with Elicio Therapeutics. Elicio will merge with a wholly owned subsidiary...
Carlyle and Abingworth’s $170 Million Non-dilutive Financing of Opthea
Goodwin Procter and Debevoise & Plimpton advised Carlyle on the deal, while Cooley and Gilbert+Tobin advised Opthea. Global investment firm Carlyle and its life sciences franchise...
Unilever’s Acquisition of a Majority Stake in Nutrafol
Cravath, Swaine & Moore represented Unilever in the transaction while Cooley advised Nutrafol. Unilever, one of the world’s leading suppliers of Beauty & Personal Care, Home...
Biote’s Business Combination Agreement with Haymaker Acquisition Corp.
Cooley advised Biote on the deal. Biote, a medical practice-building business within the hormone optimization space, announced its definitive business combination agreement with special purpose acquisition company...
Alvotech’s Merger with Oaktree Acquisition Corp. II
Cooley and Arendt advised Alvotech Holdings, while Kirkland & Ellis, working alongside Walkers and King & Spalding and Elvinger Hoss Prussen, advised Oaktree Acquisition Corp. II...
Highland Transcend Partners I’s Merger With Pharmapacks
Davis Polk advised Highland Transcend Partners I on the deal while Cooley LLP represented Packable. Highland Transcend Partners I announced its merger with Packable, the holding...